Skip to content
CompoundSci
All peptides
Research vial labelled Cagrilintide, a Incretin / GLP-1 class peptide studied in preclinical and clinical literature

Cagrilintide

Long-acting amylin analog

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

Phase II data is genuinely good, and most of it exists in combination with semaglutide rather than alone.

General profile

Class
Incretin / GLP-1 class
Evidence
Strong human evidence
Studied dose range
0.3 mg titrating upward
Frequency in protocols
Weekly
Route
Subcutaneous
Half life
~7–8 days
Reconstitution
2 mL bacteriostatic water per 5 mg vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the morning window

Once weekly, same day each week

Roughly a week long half-life, so the clock time does not matter. Slow titration is what keeps nausea manageable.

Reported cycle: 20 weeks on, run continuously in trials

Amylin analog trials titrate slowly over months. Weight regain on withdrawal is the documented pattern, so trials run continuously.

Watch for: Nausea, early satiety and any sign of undereating protein.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Separate syringesSame day fine, same syringe not

    Cagrilintide + Anything else, including another incretin

    Solo in the barrel, always

    Every incretin gets its own syringe and its own draw, including alongside another incretin. Protocol stacking is a real thing and is not a hard stop, but co-drawing is never part of it.

  • Pick oneSame day fine, same syringe not

    Cagrilintide + Another incretin in a designed protocol

    Stacking is a protocol decision, not redundancy

    Multi-incretin work uses different receptor balances, so it is not the same button pressed twice. It only makes sense with the job named first, each dose lowered against solo use, titration on response, protein defence and side effect monitoring. Insulin or sulfonylureas are physician territory.

  • Pick oneTiming

    Cagrilintide + GLP-1 analogs

    Studied together, still introduce one at a time

    The amylin plus GLP-1 combination is the actual subject of the CagriSema trials, so the pairing is documented. What is not documented is starting both in the same week: appetite suppression and nausea compound, and you cannot tell which one to slow down.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how Cagrilintide fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature